• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, November 15, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Long-term use of opioid patches common among persons with Alzheimer’s disease

Bioengineer by Bioengineer
November 14, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Approximately seven per cent of persons with Alzheimer's disease use strong pain medicines, opioids, for non-cancer pain for a period longer than six months, according to a recent study conducted at the University of Eastern Finland. One third of people initiating opioid use became long-term users, and long-term use was heavily associated with transdermal opioid patches. The results were published in PAIN.

The researchers found that long-term use of opioids was approximately as common among persons with Alzheimer's disease as it was among those without it. However, long-term use of transdermal patches was twice as common among persons with Alzheimer's disease, while tablet form opioids were more common among those without Alzheimer's disease. In addition, long-term opioid use together with benzodiazepines was common, which is worrying as both medicines cause drowsiness. The use of opioids was studied from the date of Alzheimer's disease diagnosis until death or admission into a long-term care facility. Those with active cancer treatment were excluded from the analysis.

Long-term opioid use is a problematic practice for non-cancer pain. Evidence of its benefits is limited, and the risk of adverse effects is increased compared to short-term treatment. Further, research on the benefits and adverse effects of long-term opioid use is very scarce among older adults and especially those with dementia. Changing doses and stopping medication when using patch-form opioids requires more time and thus, entails more careful monitoring. Pain, the need for analgesics, and possible adverse effects related to analgesics should be assessed regularly among persons with dementia.

The study is part of the MEDALZ cohort, which included 67,215 persons with Alzheimer's disease diagnosed during 2005-2011, of whom 13,111 initiated opioid use. Each person with the disease was matched with a comparison person without Alzheimer's disease of the same age, gender and region of residence. Data for the study were derived from Finnish nationwide registers.

###

For more information, please contact: Aleksi Hamina, MSc (Pharm), PhD student, School of Pharmacy, University of Eastern Finland, Kuopio, aleksi.hamina(at)uef.fi

Heidi Taipale, post-doctoral researcher, School of Pharmacy, University of Eastern Finland, heidi.taipale(at)uef.fi

Research article: Long-term use of opioids for non-malignant pain among community-dwelling persons with and without Alzheimer's disease in Finland: a nationwide register-based study. Aleksi Hamina, Heidi Taipale, Antti Tanskanen, Anna-Maija Tolppanen, Niina Karttunen, Liisa Pylkkänen, Jari Tiihonen, Sirpa Hartikainen. PAIN, published online 14 November 2016. doi: 10.1097/j.pain.0000000000000752

Media Contact

Aleksi Hamina
[email protected]
@UniEastFinland

http://www.uef.fi

via scienmag.com

Share12Tweet8Share2ShareShareShare2

Related Posts

Exploring Genetic Factors in Pain Post-Root Canal

Exploring Genetic Factors in Pain Post-Root Canal

November 15, 2025

Virally Delivered siRNA Targets MUC5AC to Combat Asthma

November 15, 2025

Autonomous Protein Presentation via Boolean Logic Gating

November 15, 2025

Measuring Soil-Water and Shrinkage Curves of Kaolin

November 15, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    318 shares
    Share 127 Tweet 80
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    210 shares
    Share 84 Tweet 53
  • New Research Unveils the Pathway for CEOs to Achieve Social Media Stardom

    201 shares
    Share 80 Tweet 50
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    142 shares
    Share 57 Tweet 36

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Exploring Genetic Factors in Pain Post-Root Canal

Virally Delivered siRNA Targets MUC5AC to Combat Asthma

Autonomous Protein Presentation via Boolean Logic Gating

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.